BREAKING
Biomea Fusion 2025 Financial Report 37 minutes ago Absci Corporation 2025 Financial Update 47 minutes ago MaxCyte 2025 Financial Results Review 1 hour ago Braze Fiscal Year 2026 Financial Review 1 hour ago The Trade Desk, Inc. (TTD) Drops 6.6% to $22.36 16 hours ago Etsy, Inc. (ETSY) Drops 6.9% to $48.81 16 hours ago Core & Main, Inc. (CNM) Q4 Earnings: Misses on EPS, Revenue Recap 16 hours ago LFUS (LFUS) Jumps 6.0% to $349.99 16 hours ago HIMS (HIMS) Drops 5.9% to $21.13 17 hours ago BioAge Labs 2025 Financial Results Analysis 20 hours ago Biomea Fusion 2025 Financial Report 37 minutes ago Absci Corporation 2025 Financial Update 47 minutes ago MaxCyte 2025 Financial Results Review 1 hour ago Braze Fiscal Year 2026 Financial Review 1 hour ago The Trade Desk, Inc. (TTD) Drops 6.6% to $22.36 16 hours ago Etsy, Inc. (ETSY) Drops 6.9% to $48.81 16 hours ago Core & Main, Inc. (CNM) Q4 Earnings: Misses on EPS, Revenue Recap 16 hours ago LFUS (LFUS) Jumps 6.0% to $349.99 16 hours ago HIMS (HIMS) Drops 5.9% to $21.13 17 hours ago BioAge Labs 2025 Financial Results Analysis 20 hours ago
ADVERTISEMENT
Market News

Kimberly-Clark Corporation (KMB): Main points from the Q4 2023 earnings report

Shares of Kimberly-Clark Corporation (NYSE: KMB) were down over 4% on Wednesday. The company delivered disappointing results for the fourth quarter of 2023, with both revenue and earnings missing estimates. The consumer products firm expects sales growth in the low to mid-single digits for the coming fiscal year. Here are the main points from the […]

January 24, 2024 2 min read

Shares of Kimberly-Clark Corporation (NYSE: KMB) were down over 4% on Wednesday. The company delivered disappointing results for the fourth quarter of 2023, with both revenue and earnings missing estimates. The consumer products firm expects sales growth in the low to mid-single digits for the coming fiscal year. Here are the main points from the […]

Shares of Kimberly-Clark Corporation (NYSE: KMB) were down over 4% on Wednesday. The company delivered disappointing results for the fourth quarter of 2023, with both revenue and earnings missing estimates. The consumer products firm expects sales growth in the low to mid-single digits for the coming fiscal year. Here are the main points from the earnings report:

Lower-than-expected results

Kimberly-Clark generated net sales of $4.97 billion for the fourth quarter of 2023, which was relatively flat compared to the year-ago period and lower than analysts’ projections. On an organic basis, sales grew 3%, benefiting from higher price and favorable product mix.

At the same time, the top line was negatively impacted by foreign currency headwinds and the divestiture of the tissue and K-C Professional business in Brazil. GAAP EPS for the quarter remained flat year-over-year at $1.50. Adjusted EPS fell 2% to $1.51, missing expectations.

Business performance

In Q4 2023, KMB saw organic sales growth of 3% in North America, helped by increases of 5% and 3% in Personal Care and Consumer Tissue respectively, partly offset by a 3% drop in K-C Professional (KCP). Outside North America, organic sales grew 5% in developing and emerging markets, and 1% in developed markets.

In the Personal Care segment, sales grew 2% year-over-year to $2.6 billion on a reported basis, and 6% on an organic basis, helped by favorable price, mix and volume. Sales in the Consumer Tissue segment dropped 1% to $1.5 billion in the quarter. On an organic basis, sales in this segment remained flat YoY. KCP segment sales decreased 3% YoY to $816 million, with a 1% drop on an organic basis, as lower volumes offset improved product mix and revenue realization.

Outlook

For fiscal year 2024, Kimberly-Clark expects organic sales to grow in the low-to-mid-single digits year-over-year. Adjusted EPS is expected to grow at a high-single-digit rate on a constant currency basis. Adjusted operating profit is expected to grow at a high-single-digit to low-double-digit rate on a constant currency basis.

ADVERTISEMENT